2015 Antineoplastics

2014SESSION IV OBJECTIVES: Many drug classes!

  1. Identify the differences in mechanism of action and resistance development among the various antimitotic drugs. Compare and contrast the toxicities of vinca alkaloids and taxanes. Identify the primary advantage of ixabepilone with respect to development of resistance.

  2. Describe the the differences in the use of glucocorticoids for cancer chemotherapy vs. immunosuppression.

  3. Differentiate between the mechanisms of action of the immunosuppressive antibiotics that are used for bone marrow transplantation and those that are used as antiangiogenesis inhibitors.

  4. Name the cytokines that have been approved for use in cancer treatment.  Identify the aspects of their pharmacokinetics and toxicities that are common among this class of drugs, as well as their unique mechanisms and side effects.

  5. Describe the specific targets of the monoclonal antibodies and fusion protein that are used as immunosuppressants in the treatment of leukemias.  Outline the unique mechanism that is used by denileukin diftitux to kill cancer cells.

  6. Categorize the drugs that target altered protein function with respect to the specificity of the processes that they target.  Identify the common mechanisms of action and specific side effects of antineoplastic antibodies and signal transduction inhibitors that target tyrosine kinases.

  7. Understand the mechanisms of action of L-asparagine, bortezomib and vorinostat.  Be aware of the reasoning behind the sequence of administration of methotrexate and L-asparagine.  Contrast the side effects of bortezomib and vorinostat with conventional cytotoxic drugs.

  8. Define the mechanisms of action and characteristic toxicities of tretinoin, arsenic trioxide and bexarotene.
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 13-may-15 12:19 PM